Genelux Corporation (GNLX) – What Are Researchers Thinking About This Stock?

Genelux Corporation (NASDAQ:GNLX) has earned a consensus rating of “Moderate Buy” from the four research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $20.00.

A number of research analysts recently commented on GNLX shares. Lucid Cap Mkts raised shares of Genelux to a “strong-buy” rating in a research report on Wednesday, September 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Genelux in a report on Thursday, October 15th. Wall Street Zen raised shares of Genelux from a “strong sell” rating to a “sell” rating in a report on Tuesday. Finally, Benchmark reiterated a “speculative buy” rating on shares of Genelux in a research note on Tuesday, August 18th.

Insiders Place Their Bets

In other news, insider Yong Yu sold 9,683 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $2.75, for a total value of $26,628.25. Following the completion of the sale, the insider directly owned 258,688 shares of the company’s stock, valued at $711,392. This trade represents a 3.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Thomas Zindrick sold 34,463 shares of the firm’s stock in a transaction on Monday, August 31st. The shares were sold at an average price of $2.67, for a total value of $92,016.21. Following the completion of the sale, the chief executive officer directly owned 1,226,427 shares of the company’s stock, valued at approximately $3,274,560.09. This trade represents a 2.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 47,822 shares of company stock valued at $129,482. 7.50% of the stock is owned by insiders.

Institutional Trading of Genelux

Several large investors have recently bought and sold shares of GNLX. BlackRock Inc. purchased a new stake in Genelux in the 2nd quarter valued at approximately $1,323,000. Bank of America Corp DE acquired a new stake in shares of Genelux during the 2nd quarter worth about $990,000. Flputnam Investment Management Co. acquired a new position in shares of Genelux in the second quarter valued at approximately $697,000. Global Retirement Partners LLC acquired a new stake in Genelux during the second quarter worth approximately $686,000. Finally, Citadel Advisors LLC purchased a new position in shares of Genelux during the 2nd quarter worth $257,000. Institutional investors and hedge funds own 37.33% of the company’s stock.

Genelux Stock Performance

NASDAQ GNLX opened at $2.50 on Wednesday. The firm has a market cap of $113.10 million, a price-to-earnings ratio of -2.91 and a beta of 0.59. The firm has a 50 day simple moving average of $2.56 and a 200-day simple moving average of $2.75. Genelux has a one year low of $2.29 and a one year high of $8.53.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Equities analysts predict that Genelux will post -0.81 EPS for the current fiscal year.

About Genelux

Genelux Corporation is a clinical-stage biotechnology company focused on developing novel cancer treatments based on oncolytic virus immunotherapies. The company’s platform is designed to use genetically modified viruses to selectively infect and destroy tumor cells while stimulating the patient’s immune system to recognize and attack cancer.

Genelux’s lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified vaccinia virus being studied in combination with other therapies for advanced solid tumors.